You are here

Immunity DOI:10.1016/j.immuni.2021.01.001

In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.

Publication TypeJournal Article
Year of Publication2021
AuthorsDubrot, J, Lane-Reticker, SKate, Kessler, EA, Ayer, A, Mishra, G, Wolfe, CH, Zimmer, MD, Du, PP, Mahapatra, A, Ockerman, KM, Davis, TGR, Kohnle, IC, Pope, HW, Allen, PM, Olander, KE, Iracheta-Vellve, A, Doench, JG, W Haining, N, Yates, KB, Manguso, RT
JournalImmunity
Volume54
Issue3
Pages571-585.e6
Date Published2021 Mar 09
ISSN1097-4180
Abstract

CRISPR-Cas9 genome engineering has increased the pace of discovery for immunology and cancer biology, revealing potential therapeutic targets and providing insight into mechanisms underlying resistance to immunotherapy. However, endogenous immune recognition of Cas9 has limited the applicability of CRISPR technologies in vivo. Here, we characterized immune responses against Cas9 and other expressed CRISPR vector components that cause antigen-specific tumor rejection in several mouse cancer models. To avoid unwanted immune recognition, we designed a lentiviral vector system that allowed selective CRISPR antigen removal (SCAR) from tumor cells. The SCAR system reversed immune-mediated rejection of CRISPR-modified tumor cells in vivo and enabled high-throughput genetic screens in previously intractable models. A pooled in vivo screen using SCAR in a CRISPR-antigen-sensitive renal cell carcinoma revealed resistance pathways associated with autophagy and major histocompatibility complex class I (MHC class I) expression. Thus, SCAR presents a resource that enables CRISPR-based studies of tumor-immune interactions and prevents unwanted immune recognition of genetically engineered cells, with implications for clinical applications.

DOI10.1016/j.immuni.2021.01.001
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/33497609?dopt=Abstract

Alternate JournalImmunity
PubMed ID33497609